查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971526

腦病變市場：依治療方法、病患年齡層、最終用戶和通路分類－2026-2032年全球預測

Encephalopathy Market by Treatment Type, Patient Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，腦病變市場價值將達到 2.0906 億美元，到 2026 年將成長至 2.2882 億美元，到 2032 年將達到 3.2123 億美元，複合年成長率為 6.32%。

主要市場統計數據
基準年 2025 2.0906億美元
預計年份：2026年 2.2882億美元
預測年份 2032 3.2123億美元
複合年成長率 (%) 6.32%

腦病變的基本說明，重點在於急性期和慢性期的臨床多樣性、診斷挑戰以及綜合多學科護理。

腦病變是指由多種病因引起的一系列腦功能障礙，包括代謝性疾病、肝功能障礙、感染疾病和毒物暴露。臨床上，腦病症狀表現多樣，從輕度認知障礙和行為改變到明顯的意識混亂、昏迷和重度昏迷狀態。因此，高靈敏度的診斷途徑和快速介入策略至關重要。準確區分腦病變亞型至關重要，因為治療方法和護理環境會因潛在病因、嚴重程度和合併症的不同而顯著差異。

臨床技術和政策的變革將重組腦病變的診斷、設備部署和治療護理路徑。

治療方法、醫療設備技術、數據分析和政策的同步進步正在從根本上改變腦病變治療的格局。臨床上，針對特定患者群體，人們越來越接受聯合治療方案，將旨在改變腸腦相互作用的成熟藥物與基於器械的血液淨化和肝臟支持療法相結合。這些變化得益於更精準的診斷框架，該框架降低了診斷的不確定性，縮短了治療啟動時間，使患者能夠在適當情況下更早過渡到專科干預。

分析美國關稅措施及其對腦病變治療設備和臨床服務供應鏈採購和定價的影響。

近期，美國加徵關稅引發的貿易措施，正引起整個腦病變相關治療、醫療設備和臨床服務供應鏈的關注。進口關稅及相關採購政策的變化，可能會影響血液淨化系統、血液透析機和肝臟支援平台等專用組件的相對成本和供應情況，以及成品的經銷經濟效益。這些變化可能迫使供應商和採購團隊重新審視其供應策略和庫存緩衝，以減少供應中斷。

依治療類型、通路、最終使用者和年齡層進行細分分析，決定臨床引進、照護模式和採購重點。

對腦病變治療進行有意義的細分，能夠透過協調治療方法、採購管道和醫療服務環境，制定更精準的臨床策略和商業計劃。基於治療類型的分類包括三個領域：器械、藥物和外科手術。器械領域的創新包括血液淨化系統、血液透析機和肝臟支持裝置；藥物領域著重於乳果糖和Rifaximin等藥物；外科手術包括肝臟移植和分流手術。每種治療層級都有其明確的價值提案。醫療設備著重於急性清除和器官支持功能；藥物旨在控制腸道代謝物和緩解症狀；外科手術則用於治療不可逆的器官衰竭和難治性門體分流。

美洲、歐洲、中東和非洲以及亞太地區的醫療保健系統、監管壓力和獲取途徑的區域資訊。

區域趨勢對腦病變治療方法及相關技術的可近性、應用和交付有顯著影響。這些影響必須結合當地的基礎設施、法律規範和醫療保健模式進行評估。在美洲，先進的三級醫療中心和完善的移植網路為基於器械的介入治療和複雜的外科手術提供了高容量的環境。同時，人口多樣性和支付方的異質性會影響藥物的可近性和門診追蹤。報銷談判和整合式醫療保健服務體系往往決定新技術的採用和推廣速度。

對產業參與者進行深入分析，重點在於研究合作、商業化策略和臨床差異化，從而塑造腦病變治療的創新。

主要產業參與者之間的競爭動態日益取決於整合臨床證據、技術性能和商業性可行性的能力。專注於乳果糖和Rifaximin等治療方法的成熟製藥研發公司繼續優先考慮與臨床指南的契合度、支持真實世界中的用藥依從性以及為支付方創造價值。同時，生產血液淨化系統、血液透析設備和肝臟支援平台的醫療設備製造商則專注於便攜性、易用性和服務可靠性，以拓展治療性介入的實施環境。

加強供應鏈以最佳化護理路徑並擴大肝性腦病變患者的就醫途徑的實用建議。

致力於提升腦病變治療效果的領導者應推動一系列切實可行的合作舉措，將臨床療效與營運準備緊密結合。首先，透過採購多元化、建立策略性庫存緩衝以及選擇性地在本地生產關鍵零件來強化供應鏈，可以降低貿易中斷和採購波動帶來的風險。其次，促進創新需要專注於研發，使產品功能適應實際應用環境。例如，設計既適用於醫院也適用於居家照護的血液淨化系統。

本報告清晰地概述了調查方法，包括定性和定量方法、數據三角驗證、專家檢驗以及支持研究結果的道德保障措施。

本報告的研究結合了定性和定量方法，力求兼顧臨床嚴謹性和實際應用價值。主要研究內容包括對神經內科、肝病科和重症監護科的臨床醫生、採購和供應鏈專家、臨床技術人員以及配銷通路負責人，從而實現運營和臨床觀點的三角驗證。二次分析納入了對同儕審查文獻、監管指南、設備規格和治療指南的系統性回顧，以期獲得基於現有證據和政策背景的深刻見解。

結論強調了增強腦病變治療韌性和改善患者預後的策略要求、臨床重點和協作行動。

整合臨床趨勢、技術創新、供應鏈動態和區域差異，催生了推動腦病變治療的幾個策略需求。首先，使治療方案與醫療環境的能力相符——即根據醫院、專科診所和居家照護環境調整醫療設備和服務模式——對於有效實施至關重要。其次，尤其是在合併使用醫療設備和藥物時，必須建立結合隨機對照試驗數據和真實世界結果的綜合證據，以滿足臨床懷疑者和支付者的要求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依治療方法腦病變市場

  • 醫療設備
    • 血液淨化系統
    • 血液透析機
    • 肝臟支撐裝置
  • 製藥
    • 乳果糖
    • Rifaximin
  • 手術治療
    • 肝臟移植
    • 分流手術

第9章：依患者年齡層分類的腦病變市場

  • 成人版
  • 老年人
  • 兒童

第10章：腦病變市場：依最終用戶分類

  • 居家醫療環境
  • 醫院
  • 專科診所

第11章：腦病變市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：腦病變市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：腦病變市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：腦病變市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國腦病變市場

第16章：中國腦病變市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Apotex Inc.
  • B. Braun Melsungen AG
  • Capsida Biotherapeutics
  • Cipla Limited
  • F Hoffmann-La Roche Ltd
  • Fresenius Kabi AG
  • Lupin Limited
  • Salix Pharmaceuticals, Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Xenon Pharmaceuticals
Product Code: MRR-535C62918A92

The Encephalopathy Market was valued at USD 209.06 million in 2025 and is projected to grow to USD 228.82 million in 2026, with a CAGR of 6.32%, reaching USD 321.23 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 209.06 million
Estimated Year [2026] USD 228.82 million
Forecast Year [2032] USD 321.23 million
CAGR (%) 6.32%

A focused primer on encephalopathy emphasizing clinical diversity, diagnostic challenges, and integrated multidisciplinary care across acute and chronic settings

Encephalopathy encompasses a spectrum of brain dysfunctions that arise from diverse etiologies, including metabolic derangements, hepatic insufficiency, infectious processes, and toxic exposures. Clinically, patients present along a continuum from subtle cognitive impairment and behavioral changes to overt confusion, stupor, and coma, which underscores the necessity of sensitive diagnostic pathways and rapid intervention strategies. Accurate characterization of encephalopathy subtypes is essential because therapeutic approaches and care settings vary substantially depending on the underlying driver, acuity, and comorbidities.

From an operational standpoint, the complexity of encephalopathy care requires coordinated multidisciplinary workflows that integrate neurology, hepatology, critical care, transplant services, and allied health professionals. Diagnostic advances such as enhanced neuroimaging protocols, biomarker assessment, and continuous EEG monitoring have improved detection, but variability in access to these tools affects clinical consistency. Concurrently, treatment paradigms span pharmacologic management, extracorporeal device interventions, and surgical procedures, each demanding distinct capacity, training, and procurement considerations. As a result, health systems and provider networks must calibrate clinical pathways to local capabilities while aligning outcomes measures with payer expectations.

This introduction frames encephalopathy as a clinically heterogeneous condition with significant implications for care delivery models, technology adoption, and stakeholder coordination, establishing the foundation for subsequent sections on structural change, segmentation, and actionable strategy.

Transformative overview of clinical technological and policy shifts reshaping encephalopathy diagnosis device adoption and therapeutic care pathways

The landscape of encephalopathy care is undergoing substantive transformation driven by concurrent advances in therapeutics, device technology, data analytics, and policy. Clinically, there is broader acceptance of combination approaches that pair established pharmaceuticals designed to alter gut-brain interactions with device-based blood purification and liver support modalities for select patient populations. These shifts are complemented by more precise diagnostic frameworks that reduce diagnostic uncertainty and shorten time to treatment, enabling earlier escalation to specialized interventions where appropriate.

Technological innovation is reshaping how care is delivered. Improvements in bedside blood purification systems and portable liver support platforms are expanding the potential for interventions outside the traditional intensive care environment. Simultaneously, digital tools, remote monitoring, and teleconsultation are enabling longitudinal management in home care settings and specialty clinics, which supports continuity of care and reduces reliance on inpatient resources. Payers and regulators are also influencing adoption through evolving coverage policies and value-based expectations that reward demonstrable clinical benefit and cost-efficiency.

Taken together, these dynamics are fostering new clinical pathways and commercial opportunities while placing greater emphasis on real-world evidence generation, interoperable technology, and integrated care models. Stakeholders who align clinical innovation with pragmatic deployment strategies will be best positioned to navigate this period of rapid change.

Analysis of United States tariff measures and their impacts on supply chains procurement and pricing for encephalopathy therapies devices and clinical services

Recent trade measures originating from United States tariff actions have attracted attention across the supply chain that supports encephalopathy-related therapies, devices, and clinical services. Changes in import duties and related procurement policies can affect the relative cost and availability of specialized components used in blood purification systems, hemodialysis devices, and liver support platforms, as well as the distribution economics of finished devices. These dynamics may prompt providers and procurement teams to reassess sourcing strategies and inventory buffers to mitigate disruption.

For pharmaceuticals, tariffs and trade adjustments can influence raw material sourcing and the logistics of finished-product imports, which in turn shape procurement negotiations with manufacturers and distributors. Distribution channels-from hospital pharmacies to online and retail pharmacies-may experience different operational impacts depending on tariff pass-through, fulfillment models, and contractual frameworks with suppliers. As a result, organizations may pursue increased supplier diversification, localized manufacturing options, or contractual protections to maintain supply continuity and predictable costing.

Clinically, any reconfiguration of device availability or pharmaceutical supply can cascade into treatment pathways, potentially affecting the timing of escalations to device-based therapies or surgical procedures. Therefore, strategic planning that integrates regulatory monitoring, supply chain risk assessment, and scenario-based contingency plans is essential. Health systems, manufacturers, and distributors should proactively evaluate procurement strategies and partnerships to reduce exposure and ensure that clinical quality and access are preserved amid evolving trade conditions.

Segmentation insights on treatment types distribution channels end users and age cohorts that shape clinical adoption care models and procurement priorities

Meaningful segmentation of encephalopathy care enables more precise clinical strategies and commercial planning by aligning therapeutic approaches, procurement channels, and care delivery contexts. Based on Treatment Type, the landscape is organized across Devices, Pharmaceuticals, and Surgical Procedures, where device innovation spans Blood Purification Systems, Hemodialysis Devices, and Liver Support Devices, pharmaceuticals concentrate on agents such as Lactulose and Rifaximin, and surgical pathways include Liver Transplantation and Shunt Surgeries. Each treatment class has distinct value propositions: devices emphasize acute clearance or organ support capabilities, pharmaceuticals target gut-derived metabolite control and symptom mitigation, and surgical interventions address irreversible organ failure or refractory portosystemic shunting.

Based on Distribution Channel, the pathways into clinical use are mediated through Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies, all of which present different procurement cycles, inventory management practices, and patient access considerations. Hospital pharmacies often prioritize formulary alignment and institutional protocols, online pharmacies facilitate home delivery and chronic therapy adherence, and retail pharmacies support point-of-care dispensing and patient counseling. Based on End User, clinical adoption is observed across Home Care Settings, Hospitals, and Specialty Clinics, and each end user demands tailored device form factors, support models, and training programs to enable safe and effective use.

Finally, based on Patient Age Group, therapeutic and care delivery choices vary among Adult, Geriatric, and Pediatric populations as physiological tolerance, comorbidity profiles, and caregiver involvement dictate differing clinical thresholds for escalation, device sizing, dosing strategies, and follow-up. Integrating these segmentation axes provides a holistic view that informs product development priorities, reimbursement engagement, and service delivery design.

Regional intelligence on healthcare capacity regulatory pressures and access across the Americas Europe Middle East and Africa and Asia-Pacific

Regional dynamics exert a powerful influence on the availability, adoption, and delivery of encephalopathy therapies and technologies, and they must be evaluated through the prism of local infrastructure, regulatory frameworks, and care models. In the Americas, advanced tertiary centers and established transplant networks provide high-capacity environments for device-based interventions and complex surgical procedures, while population diversity and payer heterogeneity affect access to pharmaceuticals and outpatient follow-up. Reimbursement negotiations and integrated delivery systems frequently dictate the speed with which new technologies are adopted and scaled.

In Europe, Middle East & Africa, variability is more pronounced: high-income European systems often have strong regulatory pathways and centralized procurement mechanisms that can accelerate adoption of clinically proven devices and therapeutics, whereas Middle East and African markets face constraints in specialized capacity, transplant availability, and logistics. Regional policy initiatives, cross-border procurement mechanisms, and public-private partnerships play a crucial role in bridging gaps and expanding access where infrastructure is limited.

Across Asia-Pacific, rapid investment in critical care capacity and growing focus on noncommunicable diseases are expanding demand for diagnostics and supportive technologies. However, the region also presents heterogenous regulatory timelines and local manufacturing ecosystems, which can influence commercialization strategies. Taken together, these regional nuances shape product design choices, channel prioritization, and partnership models required to achieve clinical impact and sustainable access.

Insightful analysis of industry players focusing on research collaboration commercialization strategies and clinical differentiation shaping encephalopathy care innovation

Competitive dynamics among key industry participants are increasingly defined by the ability to integrate clinical evidence, technical performance, and commercial execution. Established pharmaceutical developers that focus on therapies such as Lactulose and Rifaximin continue to emphasize clinical guidelines alignment, real-world adherence support, and payer value communication. Concurrently, medical device manufacturers that produce blood purification systems, hemodialysis hardware, and liver support platforms are concentrating on portability, ease of use, and service reliability to expand the settings in which interventions can be delivered.

Beyond product features, collaboration models are a decisive differentiator. Strategic partnerships between device providers and hospital systems, alliances with specialty clinics, and co-development arrangements with technology vendors facilitate clinical validation and adoption. Firms that invest in robust post-market evidence generation and patient support services strengthen commercial positioning by demonstrating outcomes and total-cost-of-care benefits. At the same time, regional distributors and supply-chain partners play a critical role in ensuring uptime, training, and spare-part availability, which directly impacts clinical uptake.

For industry stakeholders, the imperative is to balance innovation with pragmatic commercialization tactics: building scalable service models, capturing real-world performance data, and articulating value for multiple stakeholders to secure durable adoption across care settings.

Actionable recommendations for leaders to strengthen supply chains foster innovation optimize care pathways and expand access for encephalopathy patients

Leaders seeking to accelerate impact in encephalopathy care should pursue a set of pragmatic, coordinated actions that bridge clinical efficacy with operational readiness. First, fortifying supply chains through diversified sourcing, strategic inventory buffers, and selective localization of key components will reduce vulnerability to trade disruptions and procurement volatility. Second, fostering innovation requires targeted investment in research and development that aligns product features with deployment contexts, such as designing blood purification systems that are adaptable to both hospital and home care environments.

Third, optimizing care pathways involves close collaboration with clinical champions to embed evidence-based protocols into hospital workflows and specialty clinic pathways, while also creating scalable training programs for clinicians and technicians. Fourth, expanding access calls for engagement with payers and health authorities to secure coverage pathways and reimbursement codes that reflect both clinical benefit and cost-efficiency. Fifth, organizations should generate and communicate robust real-world evidence to demonstrate outcomes across patient cohorts, with particular attention to adult, geriatric, and pediatric populations whose needs differ materially.

Finally, pursue commercial strategies that emphasize partnership: align with distribution partners to enhance reach across hospital pharmacies, online pharmacies, and retail pharmacies, and develop patient-centric services to improve adherence and long-term outcomes. These actions, when combined, create durable advantages in both clinical impact and market execution.

Clear research methodology outlining qualitative and quantitative approaches data triangulation expert validation and ethical safeguards supporting the findings

The research underpinning this report combines qualitative and quantitative approaches designed to balance clinical rigor with practical relevance. Primary inputs include structured interviews with clinicians across neurology hepatology and critical care, procurement and supply-chain professionals, clinical engineers, and representatives from distribution channels, enabling triangulation of operational and clinical perspectives. Secondary analysis incorporated a systematic review of peer-reviewed literature, regulatory guidance, device specifications, and therapy guidelines to ground findings in current evidence and policy context.

Data triangulation methods were applied to cross-validate insights from interviews, clinical publications, and publicly available regulatory documents. Where appropriate, technology assessments evaluated device performance characteristics, serviceability, and integration requirements. Expert validation workshops were convened to test assumptions and refine recommendations against real-world operational constraints and stakeholder priorities. Ethical safeguards ensured that primary research respected confidentiality and conflict-of-interest considerations, while methodological transparency facilitated reproducibility of key analytical steps.

This mixed-method approach yields a balanced synthesis that supports strategic decision-making by combining frontline clinical insight with technical evaluation and policy awareness, providing actionable intelligence for commercialization, procurement, and clinical pathway design.

Conclusion highlighting strategic imperatives clinical priorities and coordinated actions to improve care resilience and patient outcomes in encephalopathy

The synthesis of clinical trends, technology innovation, supply-chain dynamics, and regional differentiation leads to several strategic imperatives for advancing encephalopathy care. First, aligning therapeutic choices with care-setting capabilities-matching device form factors and service models to hospitals, specialty clinics, and home care environments-will be essential for effective adoption. Second, integrated evidence generation that couples randomized data with real-world outcomes is necessary to satisfy clinical skeptics and payer requirements, particularly when devices and pharmaceuticals are used in combination.

Third, resilient procurement strategies that account for tariff exposure, supplier concentration, and logistics can help preserve continuity of care and protect institutional budgets. Fourth, segmentation-aware commercialization-recognizing differences across treatment types, distribution channels, end users, and patient age groups-enables tailored go-to-market models and reimbursement engagements. Fifth, regional strategies must be adapted to local infrastructure, regulatory timelines, and capacity constraints to ensure feasible deployment and scalability.

Collectively, these conclusions emphasize a patient-centric approach that prioritizes clinical effectiveness, operational readiness, and stakeholder alignment, providing a cohesive pathway to improve outcomes and system resilience in encephalopathy care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Encephalopathy Market, by Treatment Type

  • 8.1. Devices
    • 8.1.1. Blood Purification Systems
    • 8.1.2. Hemodialysis Devices
    • 8.1.3. Liver Support Devices
  • 8.2. Pharmaceuticals
    • 8.2.1. Lactulose
    • 8.2.2. Rifaximin
  • 8.3. Surgical Procedures
    • 8.3.1. Liver Transplantation
    • 8.3.2. Shunt Surgeries

9. Encephalopathy Market, by Patient Age Group

  • 9.1. Adult
  • 9.2. Geriatric
  • 9.3. Pediatric

10. Encephalopathy Market, by End User

  • 10.1. Home Care Settings
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Encephalopathy Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Encephalopathy Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Encephalopathy Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Encephalopathy Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Encephalopathy Market

16. China Encephalopathy Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Apotex Inc.
  • 17.7. B. Braun Melsungen AG
  • 17.8. Capsida Biotherapeutics
  • 17.9. Cipla Limited
  • 17.10. F Hoffmann-La Roche Ltd
  • 17.11. Fresenius Kabi AG
  • 17.12. Lupin Limited
  • 17.13. Salix Pharmaceuticals, Inc.
  • 17.14. Sandoz International GmbH
  • 17.15. Sun Pharmaceutical Industries Ltd.
  • 17.16. Teva Pharmaceutical Industries Ltd.
  • 17.17. Xenon Pharmaceuticals

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENCEPHALOPATHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENCEPHALOPATHY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENCEPHALOPATHY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ENCEPHALOPATHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ENCEPHALOPATHY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENCEPHALOPATHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY BLOOD PURIFICATION SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY BLOOD PURIFICATION SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY BLOOD PURIFICATION SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HEMODIALYSIS DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HEMODIALYSIS DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HEMODIALYSIS DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY LIVER SUPPORT DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY LIVER SUPPORT DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY LIVER SUPPORT DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY LACTULOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY LACTULOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY LACTULOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY RIFAXIMIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY RIFAXIMIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY RIFAXIMIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY LIVER TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY LIVER TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY LIVER TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SHUNT SURGERIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SHUNT SURGERIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SHUNT SURGERIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GCC ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 143. GCC ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 144. GCC ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 145. GCC ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GCC ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. GCC ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. G7 ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 167. G7 ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 168. G7 ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 169. G7 ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. G7 ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. G7 ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. NATO ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 175. NATO ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 176. NATO ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 177. NATO ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. NATO ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. NATO ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL ENCEPHALOPATHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES ENCEPHALOPATHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA ENCEPHALOPATHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA ENCEPHALOPATHY MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA ENCEPHALOPATHY MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA ENCEPHALOPATHY MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA ENCEPHALOPATHY MARKET SIZE, BY SURGICAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA ENCEPHALOPATHY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA ENCEPHALOPATHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA ENCEPHALOPATHY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)